Susanna Hallberg

Research

My research focuses on treatment-related immunological complications in multiple sclerosis, especially hypogammaglobulinemia, late onset neutropenia, and infection risks in rituximab and other highly efficient therapies

Article: LANCET NEUROLOGY. 2022;21(8):693-703

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.

Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J

Phd Student, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2022-2025